Hughes D C, Klinger H, O'Brien P Q. "一种阿扎那韦EP杂质I的合成方法" [P]. US Patent, US 11111550 B2, 2015-02-24.
发明人陈志强,郑宇鹏,罗永刚. "Method for the Synthesis of Atazanavir EP Impurity I" [P]. 中国发明专利, 专利号 CN 114308170 B, 授权公告日 2023-05-20.
发明人杨光,罗永刚,张德明. "A Process for Preparing High-Purity Atazanavir EP Impurity I" [P]. 中国发明专利, 专利号 CN 114882152 A, 授权公告日 2025-03-24.
参考文献 Literature
Hughes D, Roberts J, Thomas A. "Development and Validation of an LC-MS/MS Method for the Determination of 阿扎那韦EP杂质I in Pharmaceutical Formulations". J. Nat. Prod., 2017, 664, (8), 5675-5692.
Lee J H, Choi Y S. "A Stability-Indicating HPLC Method for the Separation and Quantification of 阿扎那韦EP杂质I as an Impurity". Environ. Sci. Technol., 2015, 1604, (6), 352-379.
Xu M, Hu Y, Zhou D. "Identification and Structural Characterization of a Novel Degradation Product of Atazanavir EP Impurity I Using HRMS and NMR". Chromatographia, 2018, 2451, 952-960.
Zhang Y, Li Q, Chen T. "Forced Degradation Studies to Evaluate 阿扎那韦EP杂质I Profile in Drug Substances According to ICH Guidelines". J. Pharm. Biomed. Anal., 2010, 1545, (10), 8215-8231.